Medical diagnostics specialist ANGLE has made what it calls a major breakthrough in the design of the cancer cell screener developed by its Parsortix subsidiary.

ANGLE, the intellectual property group, this morning unveiled a new and improved deal to commercialise its potentially revolutionary embryo selection technology for IVF.

The potentially revolutionary cancer cell separation device being developed by ANGLE’s subsidiary Parsortix has passed another major milestone by separating cells in blood from an actual patient.

Since the top of the market in May, £24 billion has been wiped from the value of shares held by private investors, and their total value is now £213 billion.

Recession resilient is how chief executive Andrew Jacobs describes his business, the self-storage group Lok’nStore. Indeed the company has proved its mettle in coming through the economic maelstrom of late 2008 and 2009 in better shape than when it went in.

The latest wave of reforms to the state education sector are expected to open a £53 billion market to the even greater private sector participation. This creates the perfect storm for Wey Education, a tiny PLUS-listed company set up specifically to capitalise on these fundamental changes.

ANGLE (LON:AGL) said the potentially revolutionary cell separation device being developed by its Parsortix business has been successful in capturing cultured lung cancer cells.

We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Wednesday 23rd November. ANGLE, whose star really is in the ascendancy, will be joined by Deltex Medical, Silence Therapeutics and Stanley Gibbons

ANGLE's medical diagnostics business, Parsortix, has made another important breakthrough, it was revealed today. Its cell separation device can capture prostate cancer cells.

ANGLE is the longest established of the intellectual property groups quoted on the London market. The share price rocketed recently when the group revealed Parsortix, one of its companies, had successfully tested a blood screening device that could change forever the way cancer is treated and monitored. But there is more to the group than just this one business. Proactive Investors spoke to chief executive Andrew Newland to find out more.

The technology group Angle this morning gave an incredibly bullish assessment of the prospects for the cell separation device developed by the company’s Parsortix business. In a conference call chief executive Andrew Newland revealed it is already “in dialogue” with major medical device manufacturers as it looks to realise the technology’s potential.

Recruitment group Hays put out a mixed quarterly update yesterday showing a robust performance across its overseas businesses offsetting a worrying decline in UK net fees. Indeed the downbeat outlook for its UK arm has triggered a downgrade for the stock at JP Morgan.

AIM Journal turns the spotlight on two firms with interesting back-stories hoping to make a major impact in 2011.

The speech recognition firm is profitable, it is on the verge of paying a maiden dividend and it has around £5 million on the balance sheet - equivalent to 35 per cent of the company’s market cap. Its innovative software software is used by blue-chip customers including BT, American Express, Transport for London and Barclays Stockbrokers. Yet the share price doesn't reflect any of this.

The pace of change at Management Consulting Group has been break-neck since the appointment of Nick Stagg as an executive director just over a year ago. Having laid the foundations of a growth strategy we learn a little more about his plans re-energise the company.

Thanks in large to the financial clout of those it serves, energy focused support services company Petrofac (LSE, PFC) has raced ahead throughout 2009.

It is not a secret that recruitment business is one of a cyclical nature; up when the economy is buoyant and down when otherwise.

In the financial year 2009, somewhat unsurprisingly, Big Yellow saw its occupancy rates fall to 55% (from 62% in 2008), mainly caused by new store openings.

The 3500 employees of Aggreko operate in 133 locations in 31 countries around the world; the company has some 30 years of experience of this temporary energy marketplace.